牛牛AI助理已提取核心訊息
Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, completed a purchase of 25,974 shares of common stock on January 31, 2024. The transaction was carried out on the open market at a price of $0.375 per share, resulting in a total investment of $9,740.25. Following this acquisition, Dow's direct holdings in the company increased to 703,599 shares. The transaction underscores the CEO's confidence in the company and provides investors with a signal regarding the leadership's view of the stock's value.
Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, completed a purchase of 25,974 shares of common stock on January 31, 2024. The transaction was carried out on the open market at a price of $0.375 per share, resulting in a total investment of $9,740.25. Following this acquisition, Dow's direct holdings in the company increased to 703,599 shares. The transaction underscores the CEO's confidence in the company and provides investors with a signal regarding the leadership's view of the stock's value.
60 Degrees Pharmicals總裁兼首席執行官傑弗裏·陶於2024年1月31日完成了對25,974股普通股的購買。該交易在公開市場上進行，價格爲每股0.375美元，總投資額爲9,740.25美元。此次收購後，陶氏在該公司的直接持股量增加到703,599股。該交易凸顯了首席執行官對公司的信心，併爲投資者提供了有關領導層對股票價值的看法的信號。
60 Degrees Pharmicals總裁兼首席執行官傑弗裏·陶於2024年1月31日完成了對25,974股普通股的購買。該交易在公開市場上進行，價格爲每股0.375美元，總投資額爲9,740.25美元。此次收購後，陶氏在該公司的直接持股量增加到703,599股。該交易凸顯了首席執行官對公司的信心，併爲投資者提供了有關領導層對股票價值的看法的信號。
有用
沒用